title: Cost effectiveness analysis of antenatal HIV screening in United Kingdom.
abstract: OBJECTIVE
  To assess the cost effectiveness of universal antenatal HIV screening compared with selective screening in the United Kingdom.
  
  
  METHODS
  Incremental cost effectiveness analysis relating additional costs of screening to life years gained. Maternal and paediatric costs and life years were combined.
  
  
  METHODS
  United Kingdom.
  
  
  METHODS
  Number of districts for which universal screening would be cost effective compared with selective screening under various conditions.
  
  
  RESULTS
  On base case assumptions, a new diagnosis of a pregnant woman with HIV results in a gain of 6.392 life years and additional expenditure of 14 833 pounds. If decision makers are prepared to pay up to 10 000 pounds an additional life year, this would imply a net benefit of 49 090 pounds (range 12 300 pounds- 59 000 pounds), which would be available to detect each additional infected woman in an antenatal screening programme. In London, universal antenatal screening would be cost effective compared with a selective screening under any reasonable assumptions about screening costs. Outside London, universal screening with uptake above 90% would be cost effective with a 0.60 pounds HIV antibody test cost and up to 3.5 minutes for pretest discussion. Cost effectiveness of universal testing is lower if selective testing can achieve high uptake among those at higher risk. A universal strategy with only 50% uptake may not be less cost effective in low prevalence districts and may cost more and be less effective than a well run selective strategy.
  
  
  CONCLUSIONS
  Universal screening with pretest discussion should be adopted throughout the United Kingdom as part of routine antenatal care as long as test costs can be kept low and uptake high.
authors.affiliation: Department of Epidemiology, Institute of Child Health, London WC1N 1EH. a.ades@ich.ucl.ac.uk
authors.forename: A E
authors.initials: AE
authors.lastname: Ades
authors.forename: M J
authors.initials: MJ
authors.lastname: Sculpher
authors.forename: D M
authors.initials: DM
authors.lastname: Gibb
authors.forename: R
authors.initials: R
authors.lastname: Gupta
authors.forename: J
authors.initials: J
authors.lastname: Ratcliffe
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D008403:Mass Screening / Q000191:economics; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000191:economics*; D011379:Prognosis; D006113:United Kingdom
chemical_list: D019380:Anti-HIV Agents